JP4671384B2 - New lactic acid strain - Google Patents
New lactic acid strain Download PDFInfo
- Publication number
- JP4671384B2 JP4671384B2 JP2001144841A JP2001144841A JP4671384B2 JP 4671384 B2 JP4671384 B2 JP 4671384B2 JP 2001144841 A JP2001144841 A JP 2001144841A JP 2001144841 A JP2001144841 A JP 2001144841A JP 4671384 B2 JP4671384 B2 JP 4671384B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- lactobacillus gasseri
- strain
- osmotic pressure
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、胆汁酸耐性能及び浸透圧耐性能を有するラクトバチルス・ガセリ(Lactobacillus gasseri)菌株に関する。
【0002】
【従来の技術】
近年、生理効果を有する乳酸菌が注目されている。特に、生きた状態で腸管に到達し、宿主に対して有効な保健効果を示す乳酸菌は、プロバイオティクス乳酸菌と定義され、ビフィドバクテリウム属菌やラクトバチルス属菌等の乳酸菌が注目されている。そして、これらの乳酸菌に関しては、整腸効果や消化吸収能の改善、血清コレステロールの低減、抗腫瘍効果等数多くの保健効果について報告されている。
【0003】
ところで、これらのプロバイオティクス乳酸菌が消化管内で有効に働き保健効果を発揮するには、生きたままの状態で消化管内に到達する必要がある。しかし、消化管内に到達するまでに、温度、pH、酸素、浸透圧、胃酸や胆汁酸等、プロバイオティクス乳酸菌にとって様々な生育阻害環境や生育阻害物質が存在している。したがって、プロバイオティクス乳酸菌を利用するに際しては、そのプロバイオティクス乳酸菌が生育阻害環境や生育阻害物質に対して耐性能を有しているか否かが重要である。
【0004】
特に、プロバイオティクス乳酸菌を凍結乾燥する過程での急激な水分活性の変化により、あるいはプロバイオティクス乳酸菌を利用した製品を製造する過程での糖類や塩類等の添加により、プロバイオティクス乳酸菌は、浸透圧によるストレスを受ける。したがって、浸透圧耐性能を有することは、プロバイオティクス乳酸菌にとって有利で有用な性質の一つであるといえる。また、プロバイオティクス乳酸菌を摂取した場合、強い界面活性効果と細胞膜に直接作用する殺菌効果とを示す胆汁酸が腸管内に存在していて、大きな影響を与えると考えられるので、胆汁酸耐性能を有することは、プロバイオティクス乳酸菌にとって有利で有用な性質の一つであるといえる。
【0005】
なお、胆汁酸は、ヒトをはじめ多くの動物の肝臓で生成される物質である。肝臓でコレステロールから生成されたコール酸やケノデオキシコール酸等の胆汁酸は一次胆汁酸と呼ばれ、タウリンやグリシンと結合して抱合型胆汁酸となり、胆汁中に分泌される。そして、胆汁中に分泌された大部分の胆汁酸は、腸管から吸収されて肝臓へ戻り、再び胆汁中に分泌されるという腸肝循環を繰り返している。また、一次胆汁酸の中には、腸管内において腸内細菌の作用により脱水酸化され、デオキシコール酸やリトコール酸等の二次胆汁酸と呼ばれる胆汁酸に変換されるものもある。
【0006】
【発明が解決しようとする課題】
本発明者らは、プロバイオティクス乳酸菌として利用が可能な菌株を取得するべく、鋭意研究を進めてきたところ、ラクトバチルス・ガセリ(Lactobacillus gasseri)に属する菌株の中から胆汁酸耐性能及び浸透圧耐性能を有するラクトバチルス・ガセリ(Lactobacillus gasseri)変異株を取得することに成功し、本発明を完成するに至った。したがって、本発明は、プロバイオティクス乳酸菌として保健効果が期待できる、胆汁酸耐性能及び浸透圧耐性能を有するラクトバチルス・ガセリ(Lactobacillus gasseri)の菌株を提供することを課題とする。
【0007】
【課題を解決するための手段】
本発明は、胆汁酸耐性能及び浸透圧耐性能を有するラクトバチルス・ガセリ(Lactobacillus gasseri)の新規な菌株であり、例えば、グリココール酸24%、グリコケノデオキシコール酸24%、グリコデオキシコール酸18%、タウロコール酸13%、タウロケノデオキシコール酸13%及びタウロデオキシコール酸8%からなる抱合型胆汁酸混合液を10mM以上含有する培地で生育可能な胆汁酸耐性能を有するものであり、かつ浸透圧2.2 Osmol/kg以上の培地で生育可能な浸透圧耐性能を有するものである。この新規な菌株は、ラクトバチルス・ガセリ(Lactobacillus gasseri)の変異株であり、例えば、ラクトバチルス・ガセリ(Lactobacillus gasseri)SBT10801(FERM P-18137)である。
【0008】
本発明の胆汁酸耐性能及び浸透圧耐性能を有するラクトバチルス・ガセリ(Lactobacillus gasseri)菌株は、以下のようにして取得することができる。
すなわち、ヒト糞便を、光岡の LBS寒天培地に塗末し、嫌気条件下、37℃で3 日間培養して得られるコロニーを分離する。そして、この菌株を Bergy's Manual of systematic bacteriology, vol.2(1986) に従って同定した結果、ラクトバチルス・ガセリ(Lactobacillus gasseri)の菌学的性質と一致した。しかも、ラクトバチルス・ガセリ(Lactobacillus gasseri)の基準株であるラクトバチルス・ガセリ(Lactobacillus gasseri) JCM1131と同等の性質を有していた。これをラクトバチルス・ガセリ(Lactobacillus gasseri) SBT0269と命名し、これを親株とし、グリココール酸24%、グリコケノデオキシコール酸24%、グリコデオキシコール酸18%、タウロコール酸13%、タウロケノデオキシコール酸13%及びタウロデオキシコール酸8%からなる抱合型胆汁酸混合液を5mM含有する培地に接種し、生育した菌株を分離する。そして、培地中に添加する抱合型胆汁酸混合液の濃度を段階的に高めて生育した菌株を分離し、最終的に抱合型胆汁酸混合液を10mM含有する培地で生育した菌株を分離して、胆汁酸耐性能を有するラクトバチルス・ガセリ(Lactobacillus gasseri)の菌株を得る。
【0009】
次に、分離した胆汁酸耐性能を有するラクトバチルス・ガセリ(Lactobacillus gasseri)の菌株を親株とし、浸透圧1.5 Osmol/kgの培地に接種し、生育した菌株を分離する。そして、培地の浸透圧を段階的に高めて生育した菌株を分離して、最終的に浸透圧2.2 Osmol/kgの培地で生育した菌株を分離して、胆汁酸耐性能を有すると共に浸透圧耐性能を有するラクトバチルス・ガセリ(Lactobacillus gasseri)の菌株を得る。
【0010】
このようにして得られる菌株は、胆汁酸耐性能及び浸透圧耐性能を有するラクトバチルス・ガセリ(Lactobacillus gasseri)の変異株であり、ラクトバチルス・ガセリ(Lactobacillus gasseri)の新規な菌株である。
本発明のラクトバチルス・ガセリ(Lactobacillus gasseri)は、前記のようなヒト胆汁酸組成を参考にしてデザインされた抱合型胆汁酸混合物で生育可能であるから、ヒトの胆汁中で生育することができる。
さらに、浸透圧 2.2 Osmol/kg 以上の培地で生育することができる。浸透圧2.2 Osmol/kgを塩化ナトリウム濃度に換算すると約1Mでショ糖濃度43%に相当する。従って、このような浸透圧を有する加糖タイプの発酵乳や漬物等の高浸透圧食品中でも充分生育することができる。
【0011】
この菌株は、下記の菌学的性質を有しており、後記した理由からラクトバチルス・ガセリ(Lactobacillus gasseri)に属する菌株であることが確認できたので、ラクトバチルス・ガセリ(Lactobacillus gasseri)SBT10801と命名され、工業技術院生命工学工業技術研究所に、FERM P-18137として寄託されている。その菌学的性質は以下の通りである。
【0012】
A 形態的性状
1.細胞の形:桿菌
2.胞子の有無:なし
3.グラム染色:陽性
B 培地上の生育状態
1.プレートカウントアガー培地上のコロニー形態:表面が滑らかな白色球状
【0013】
C 生理的性質
15℃での生育能:陰性
45℃での生育能:陽性
アルギニンの分解性:陰性
生成した乳酸の型:DL
各種炭水化物の分解性(陽性+、陰性−)
アミグダリン:+
アラビノース:−
セロビオース:−
フルクトース:−
ガラクトース:+
グルコース:+
ラクトース:+
グルコネート:−
マルトース:+
マンニトール:−
マンノース:+
ラムノース:−
リボース:−
ソルビトール:+
シュークロース:+
キシロース:−
【0014】
上記の菌学的性質から、Bergy's Manual of systematic bacteriology, vol.2 (1986) により同定すると、ラクトバチルス・ガセリ(Lactobacillus gasseri) SBT10801(FERM P-18137)は、ラクトバチルス・ガセリ(Lactobacillus gasseri)の菌学的性質と一致した。
このラクトバチルス・ガセリ(Lactobacillus gasseri) SBT10801(FERM P-18137)は、グリココール酸24%、グリコケノデオキシコール酸24%、グリコデオキシコール酸18%、タウロコール酸13%、タウロケノデオキシコール酸13%及びタウロデオキシコール酸8%からなる抱合型胆汁酸混合液を15mM含有する培地で生育可能なものであり、かつ浸透圧2.2 Osmol/kg以上の培地で生育可能なものであって、この点において標準のラクトバチルス・ガセリ(Lactobacillus gasseri)と相違し、胆汁酸耐性能及び浸透圧耐性能を有するラクトバチルス・ガセリ(Lactobacillus gasseri)の変異株である。
【0015】
次に、実施例及び試験例を示し、本発明をさらに詳しく説明する。
【実施例1】
胆汁酸及び浸透圧に対して、ラクトバチルス・ガセリ(Lactobacillus gasseri)の基準株であるラクトバチルス・ガセリ(Lactobacillus gasseri) JCM1131と同等の耐性を有するラクトバチルス・ガセリ(Lactobacillus gasseri) SBT0269を親株とし、グリココール酸24%、グリコケノデオキシコール酸24%、グリコデオキシコール酸18%、タウロコール酸13%、タウロケノデオキシコール酸13%及びタウロデオキシコール酸8%からなる抱合型胆汁酸混合液を5mM 含有するMRS培地に接種し、37℃で生育が認められるまで約 120時間培養した。そして、5.5mM 胆汁酸を含有する培地にこの培養液を5%接種し、同様に37℃で約 120時間培養した。
このようにして、MRS培地に添加する抱合型胆汁酸混合液の濃度を 0.5mMずつ段階的に高めて生育した菌株を分離し、最終的に10mMの抱合型胆汁酸混合液を含有するMRS培地で生育した菌株を分離した。培養時間は、菌株の生育状況に応じて 240時間まで培養を行った。
なお、MRS培地は、培地1リットル当たり、次の組成を有する;
プロトースペプトンNo.3 10g、ビーフエクストラクト10g 、イーストエクストラクト5g、デキストロース 20g、ツィーン80 1g 、クエン酸アンモニウム2g、酢酸ナトリウム5g、硫酸マグネシウム0.1g、硫酸マンガン0.05g 及びリン酸第二カリウム2g。
【0016】
次に、分離した菌株を浸透圧1.5 Osmol/kgのMRS培地に接種し、生育した菌株を分離した。培地の浸透圧の調整はMRS培地に塩化ナトリウムを添加することにより行った。そして、この培養液を浸透圧1.6 Osmol/kgのMRS培地に 5%接種し、同様に37℃で約 120時間培養した。
このようにして、MRS培地の浸透圧を 0.1 Osmol/kg ずつ段階的に高めて生育した菌株を分離し、最終的に培地の浸透圧が 2.2 Osmol/kg のMRS培地で生育した菌株を分離した。なお、培養時間は、菌株の生育状況に応じて 240時間まで培養を行った。
得られた変異株を、通常のMRS培地で3〜7代継代培養した後、10mM胆汁酸を含む培地又は1M塩化ナトリウムを含む培地に、5%接種して生育させた。
このようにして得られたラクトバチルス・ガセリ(Lactobacillus gasseri)の変異株は、胆汁酸耐性能及び浸透圧耐性能を有するラクトバチルス・ガセリ(Lactobacillus gasseri)の新規な菌株であり、ラクトバチルス・ガセリ(Lactobacillus gasseri) SBT10801 (FERM P-18137)として工業技術院生命工学工業技術研究所に寄託した。
【0017】
なお、親株は抱合型胆汁酸混合液を6mM 含有する培地で生育が阻害されるのに対し、変異株は抱合型胆汁酸混合液を15mM含有する培地で生育することができ、また、親株は浸透圧1.6 Osmol/kgの培地で生育が阻害されるのに対し、変異株は浸透圧2.2 Osmol/kgの培地で生育することができる。
【0018】
【試験例1】
実施例1で得られた胆汁酸耐性能及び浸透圧耐性能を有するラクトバチルス・ガセリ(Lactobacillus gasseri) SBT10801 (FERM P-18137)を、培地中に添加する前記抱合型胆汁酸混合液の濃度を 0〜20mMの範囲で段階的に高めて調製したMRS培地に接種し、37℃で8時間培養して、それぞれの生育状態を比較した。また、親株のラクトバチルス・ガセリ(Lactobacillus gasseri)SBT0269 及び基準株のラクトバチルス・ガセリ(Lactobacillus gasseri) JCM1131についても、同様にして、それぞれの生育状態を比較した。なお、生育状態は、培地の濁度を測定することにより評価した。すなわち、抱合型胆汁酸混合液無添加のMRS培地で培養した場合の培養液の660nm におけるOD値を100 とし、抱合型胆汁酸混合液添加のそれぞれのMRS培地で培養した場合の培養液の660nm におけるOD値を百分率で表した。その結果を図1に示す。
【0019】
親株のラクトバチルス・ガセリ(Lactobacillus gasseri) SBT0269や基準株のラクトバチルス・ガセリ(Lactobacillus gasseri) JCM1131では、抱合型胆汁酸混合液を 5〜6mM 含有する培地で生育が阻害されたのに対して、本発明のラクトバチルス・ガセリ(Lactobacillus gasseri) SBT10801 (FERM P-18137)では、抱合型胆汁酸の濃度が高くなるにつれ生育状態は悪くなるものの、抱合型胆汁酸混合液を15mM含有する培地でも生育できることが判った。
【0020】
【試験例2】
実施例1で得られた胆汁酸耐性能及び浸透圧耐性能を有するラクトバチルス・ガセリ(Lactobacillus gasseri) SBT10801 (FERM P-18137)をMRS培地で培養した後、遠心分離して菌体を回収した。そして、食塩で浸透圧2.2 Osmol/kgに調整したMRS培地に回収した菌体を懸濁して10℃で保存し、経時的にプレートカウント法で生菌数を測定して、生育状態を比較した。また、親株のラクトバチルス・ガセリ(Lactobacillus gasseri) SBT0269及び基準株のラクトバチルス・ガセリ(Lactobacillus gasseri) JCM1131 についても、同様にして、それぞれの生育状態を比較した。その結果を図2に示す。
親株のラクトバチルス・ガセリ(Lactobacillus gasseri) SBT0269や基準株のラクトバチルス・ガセリ(Lactobacillus gasseri) JCM1131では、保存開始21日後で生菌数が106 cfu/ml以下に減少したのに対して、本発明のラクトバチルス・ガセリ(Lactobacillus gasseri) SBT10801 (FERM P-18137)では、保存開始21日後で生菌数が108 cfu/mlであり、生菌数の減少は殆ど見られなかった。
【0021】
【発明の効果】
本発明のラクトバチルス・ガセリ(Lactobacillus gasseri) SBT10801 (FERM P-18137)は、高い胆汁酸耐性能及び浸透圧耐性能を有しているので、胆汁酸濃度の高い腸管内や浸透圧の高い環境下において高い生残性が期待でき、プロバイオティクス乳酸菌として有用である。
【図面の簡単な説明】
【図1】試験例1におけるラクトバチルス・ガセリ(Lactobacillus gasseri)の各菌株の生育状態を示す。
【符号の説明】
黒 丸:SBT10801
黒三角:SBT0269
黒四角:JCM1131
【図2】試験例2におけるラクトバチルス・ガセリ(Lactobacillus gasseri)の各菌株の生菌数を示す。
【符号の説明】
黒 丸:SBT10801
黒三角:SBT0269
黒四角:JCM1131[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a Lactobacillus gasseri strain having bile acid resistance and osmotic pressure resistance.
[0002]
[Prior art]
In recent years, lactic acid bacteria having physiological effects have attracted attention. In particular, lactic acid bacteria that reach the intestinal tract in a living state and show effective health effects on the host are defined as probiotic lactic acid bacteria, and lactic acid bacteria such as Bifidobacterium and Lactobacillus are attracting attention. Yes. And about these lactic acid bacteria, many health effects, such as an intestinal regulation effect and improvement of digestion absorption ability, reduction of serum cholesterol, an antitumor effect, are reported.
[0003]
By the way, in order for these probiotic lactic acid bacteria to work effectively in the digestive tract and exert health effects, it is necessary to reach the digestive tract while remaining alive. However, before reaching the digestive tract, there are various growth-inhibiting environments and growth-inhibiting substances for probiotic lactic acid bacteria such as temperature, pH, oxygen, osmotic pressure, stomach acid and bile acid. Therefore, when using a probiotic lactic acid bacterium, it is important whether the probiotic lactic acid bacterium has resistance to a growth-inhibiting environment or a growth-inhibiting substance.
[0004]
In particular, probiotic lactic acid bacteria, due to a rapid change in water activity in the process of freeze-drying probiotic lactic acid bacteria, or addition of sugars, salts, etc. in the process of producing products using probiotic lactic acid bacteria, Receive stress from osmotic pressure. Therefore, it can be said that having osmotic pressure resistance is one of the advantageous and useful properties for probiotic lactic acid bacteria. In addition, when ingesting probiotic lactic acid bacteria, bile acids that have a strong surface-active effect and a bactericidal effect that acts directly on the cell membrane are present in the intestinal tract and are thought to have a significant impact on the bile acid resistance. It can be said that it is one of advantageous and useful properties for probiotic lactic acid bacteria.
[0005]
Bile acid is a substance produced in the livers of many animals including humans. Bile acids such as cholic acid and chenodeoxycholic acid generated from cholesterol in the liver are called primary bile acids, which are combined with taurine and glycine to form conjugated bile acids and are secreted into the bile. And most bile acids secreted in the bile are absorbed from the intestinal tract, return to the liver, and repeat the enterohepatic circulation where it is secreted again in the bile. Some primary bile acids are dehydrated and oxidized in the intestine by the action of intestinal bacteria, and converted into bile acids called secondary bile acids such as deoxycholic acid and lithocholic acid.
[0006]
[Problems to be solved by the invention]
The present inventors have been diligently researched to obtain a strain that can be used as a probiotic lactic acid bacterium, and as a result, among the strains belonging to Lactobacillus gasseri , bile acid resistance and osmotic pressure. The present inventors have succeeded in obtaining a Lactobacillus gasseri mutant strain having durability, and have completed the present invention. Accordingly, an object of the present invention is to provide a strain of Lactobacillus gasseri that can be expected to have a health effect as a probiotic lactic acid bacterium and has bile acid resistance and osmotic pressure resistance.
[0007]
[Means for Solving the Problems]
The present invention is a novel strain of Lactobacillus gasseri having bile acid resistance and osmotic pressure resistance, for example, glycocholic acid 24%, glycochenodeoxycholic acid 24%, glycodeoxycholic acid 18% It has a bile acid resistance capable of growing in a medium containing 10 mM or more of a conjugated bile acid mixture composed of 13% taurocholic acid, 13% taurochenodeoxycholic acid and 8% taurodeoxycholic acid, and has an osmotic pressure of 2.2. It has osmotic pressure resistance and can grow in a medium of Osmol / kg or more. This novel strain is a mutant strain of Lactobacillus gasseri , for example, Lactobacillus gasseri SBT10801 (FERM P-18137).
[0008]
The Lactobacillus gasseri strain having bile acid resistance and osmotic pressure resistance according to the present invention can be obtained as follows.
That is, human feces are smeared on Mitsuoka's LBS agar medium and colonies obtained by culturing at 37 ° C. for 3 days under anaerobic conditions are isolated. As a result of identifying this strain according to Bergy's Manual of systematic bacteriology, vol. 2 (1986), it was consistent with the mycological properties of Lactobacillus gasseri . Moreover, it had properties equivalent Lactobacillus gasseri (Lactobacillus gasseri) JCM1131 and a reference strain of Lactobacillus gasseri (Lactobacillus gasseri). This is named Lactobacillus gasseri SBT0269, which is the parent strain, and is glycocholic acid 24%, glycochenodeoxycholic acid 24%, glycodeoxycholic acid 18%, taurocholic acid 13%, taurochenodeoxycholic acid 13% and A medium containing 5 mM of a conjugated bile acid mixture consisting of 8% taurodeoxycholic acid is inoculated to isolate the grown strain. Then, isolate the strain that grew by gradually increasing the concentration of the conjugated bile acid mixture added to the medium, and finally isolate the strain that grew on the medium containing 10 mM of the conjugated bile acid mixture. A strain of Lactobacillus gasseri having bile acid resistance is obtained.
[0009]
Next, the isolated strain of Lactobacillus gasseri having resistance to bile acid is used as a parent strain and inoculated into a medium having an osmotic pressure of 1.5 Osmol / kg to isolate the grown strain. Then, isolate the strain that grew by gradually increasing the osmotic pressure of the medium, and finally isolate the strain that grew on the medium of osmotic pressure 2.2 Osmol / kg. A strain of Lactobacillus gasseri having performance is obtained.
[0010]
The strain thus obtained is a mutant strain of Lactobacillus gasseri having bile acid resistance and osmotic pressure resistance, and is a novel strain of Lactobacillus gasseri .
The Lactobacillus gasseri of the present invention can be grown in a conjugated bile acid mixture designed with reference to the human bile acid composition as described above, and thus can grow in human bile. .
Furthermore, it can grow on a medium having an osmotic pressure of 2.2 Osmol / kg or more. When the osmotic pressure 2.2 Osmol / kg is converted into the sodium chloride concentration, it is about 1 M, which corresponds to a sucrose concentration of 43%. Therefore, it can grow sufficiently even in high osmotic pressure foods such as sweetened fermented milk and pickles having such osmotic pressure.
[0011]
This strain has the following bacteriological properties, and since it was confirmed that it belongs to Lactobacillus gasseri for the reasons described below, Lactobacillus gasseri SBT10801 and Named and deposited as FERM P-18137 at the Institute of Biotechnology, National Institute of Advanced Industrial Science and Technology. Its mycological properties are as follows.
[0012]
A Morphological properties Cell shape: Neisseria gonorrhoeae 2. Presence or absence of spores: None Gram staining: positive B Growth state on medium Colony morphology on plate count agar medium: white sphere with smooth surface
C Physiological properties
Viability at 15 ° C: negative
Growth ability at 45 ° C: Degradability of positive arginine: Negative Type of lactic acid produced: DL
Degradability of various carbohydrates (positive +, negative-)
Amygdalin: +
Arabinose:-
Cellobiose:-
Fructose:-
Galactose: +
Glucose: +
Lactose: +
Gluconate:-
Maltose: +
Mannitol:-
Mannose: +
Rhamnose:-
Ribose:-
Sorbitol: +
Sucrose: +
Xylose:-
[0014]
From mycological properties of the above, Bergy's Manual of systematic bacteriology, vol.2 of (1986) and is identified by, Lactobacillus gasseri (Lactobacillus gasseri) SBT10801 (FERM P -18137) , the Lactobacillus gasseri (Lactobacillus gasseri) Consistent with mycological properties.
This Lactobacillus gasseri SBT10801 (FERM P-18137) is composed of glycocholic acid 24%, glycochenodeoxycholic acid 24%, glycodeoxycholic acid 18%, taurocholic acid 13%, taurochenodeoxycholic acid 13% and taurodeoxy It can grow on a medium containing 15 mM of a conjugated bile acid mixture consisting of 8% cholic acid, and can grow on a medium having an osmotic pressure of 2.2 Osmol / kg or higher. Unlike Lactobacillus gasseri, it is a mutant strain of Lactobacillus gasseri having bile acid resistance and osmotic pressure resistance.
[0015]
Next, the present invention will be described in more detail with reference to examples and test examples.
[Example 1]
Against bile acids and osmotic pressure, Lactobacillus gasseri (Lactobacillus gasseri) SBT0269 with Lactobacillus gasseri (Lactobacillus gasseri) JCM1131 equivalent resistance is the reference strain of Lactobacillus gasseri (Lactobacillus gasseri) with the parent strain, MRS medium containing 5 mM conjugated bile acid mixture consisting of 24% glycocholic acid, 24% glycochenodeoxycholic acid, 18% glycodeoxycholic acid, 13% taurocholic acid, 13% taurochenodeoxycholic acid and 8% taurodeoxycholic acid And cultured at 37 ° C. for about 120 hours until growth was observed. Then, 5% of this culture solution was inoculated into a medium containing 5.5 mM bile acid, and similarly cultured at 37 ° C. for about 120 hours.
In this way, the strain grown by gradually increasing the concentration of the conjugated bile acid mixture added to the MRS medium by 0.5 mM stepwise is isolated, and finally the MRS medium containing the 10 mM conjugated bile acid mixture is added. The strains that grew on were isolated. The culture time was up to 240 hours depending on the growth of the strain.
MRS medium has the following composition per liter of medium;
Protospepton No. 3 10 g, Beef Extract 10 g, Yeast Extract 5 g, Dextrose 20 g,
[0016]
Next, the isolated strain was inoculated into an MRS medium having an osmotic pressure of 1.5 Osmol / kg to isolate the grown strain. The osmotic pressure of the medium was adjusted by adding sodium chloride to the MRS medium. Then, 5% of this culture solution was inoculated into an MRS medium having an osmotic pressure of 1.6 Osmol / kg, and cultured at 37 ° C. for about 120 hours.
In this way, the strain that grew by gradually increasing the osmotic pressure of the MRS medium by 0.1 Osmol / kg was isolated, and finally the strain that grew on the MRS medium having the medium osmotic pressure of 2.2 Osmol / kg was isolated. . The culture time was up to 240 hours depending on the growth of the strain.
The obtained mutant strain was subcultured for 3 to 7 passages in a normal MRS medium, and then inoculated and grown in a medium containing 10 mM bile acid or a medium containing 1 M sodium chloride.
The mutant strain of Lactobacillus gasseri thus obtained is a novel strain of Lactobacillus gasseri having bile acid resistance and osmotic pressure resistance, and Lactobacillus gasseri. (Lactobacillus gasseri) SBT10801 (FERM P-18137) was deposited at the Institute of Biotechnology, National Institute of Advanced Industrial Science and Technology.
[0017]
The parent strain is inhibited from growing in a medium containing 6 mM of a conjugated bile acid mixture, whereas the mutant strain can grow in a medium containing 15 mM of a conjugated bile acid mixture. The growth is inhibited by a medium having an osmotic pressure of 1.6 Osmol / kg, whereas the mutant strain can grow on a medium having an osmotic pressure of 2.2 Osmol / kg.
[0018]
[Test Example 1]
The concentration of the conjugated bile acid mixture obtained by adding Lactobacillus gasseri SBT10801 (FERM P-18137) having bile acid resistance and osmotic pressure resistance obtained in Example 1 to the medium is determined. The inoculated MRS medium prepared stepwise in the range of 0 to 20 mM was cultured at 37 ° C. for 8 hours, and the growth states were compared. In addition, the growth state of Lactobacillus gasseri SBT0269 and the reference strain Lactobacillus gasseri JCM1131 were also compared in the same manner. The growth state was evaluated by measuring the turbidity of the medium. That is, the OD value at 660 nm of the culture solution when cultured in the MRS medium not added with the conjugated bile acid mixture is set to 100, and the 660 nm of the culture solution when cultured in each MRS medium added with the conjugated bile acid mixture solution. The OD value was expressed as a percentage. The result is shown in FIG.
[0019]
In the parent strain Lactobacillus gasseri SBT0269 and the reference strain Lactobacillus gasseri JCM1131, growth was inhibited in a medium containing 5-6 mM conjugated bile acid mixture, Lactobacillus gasseri SBT10801 (FERM P-18137) of the present invention grows in a medium containing 15 mM of a conjugated bile acid mixture, although the growth state worsens as the concentration of conjugated bile acid increases. I found that I can do it.
[0020]
[Test Example 2]
Lactobacillus gasseri SBT10801 (FERM P-18137) having bile acid resistance and osmotic pressure resistance obtained in Example 1 was cultured in MRS medium, and then centrifuged to recover the cells. . Then, the recovered cells were suspended in MRS medium adjusted to an osmotic pressure of 2.2 Osmol / kg with salt and stored at 10 ° C., and the number of viable cells was measured over time by the plate count method, and the growth state was compared. . Similarly, the growth conditions of the parent strain Lactobacillus gasseri SBT0269 and the reference strain Lactobacillus gasseri JCM1131 were also compared. The result is shown in FIG.
In the parent strain Lactobacillus gasseri SBT0269 and the reference strain Lactobacillus gasseri JCM1131, the number of viable bacteria decreased to 10 6 cfu / ml or less 21 days after the start of storage. In the Lactobacillus gasseri SBT10801 (FERM P-18137) of the invention, the viable cell count was 10 8 cfu /
[0021]
【The invention's effect】
Lactobacillus gasseri SBT10801 (FERM P-18137) of the present invention has a high bile acid resistance and osmotic pressure resistance, so the bile acid concentration is high in the intestinal tract and high osmotic pressure environment High survival can be expected below, and it is useful as a probiotic lactic acid bacterium.
[Brief description of the drawings]
1 shows the growth state of each strain of Lactobacillus gasseri in Test Example 1. FIG.
[Explanation of symbols]
Black circle: SBT10801
Black triangle: SBT0269
Black square: JCM1131
2 shows the number of viable bacteria of each strain of Lactobacillus gasseri in Test Example 2. FIG.
[Explanation of symbols]
Black circle: SBT10801
Black triangle: SBT0269
Black square: JCM1131
Claims (2)
胆汁酸耐性能が、グリココール酸24%、グリコケノデオキシコール酸24%、グリコデオキシコール酸18%、タウロコール酸13%、タウロケノデオキシコール酸13%及びタウロデオキシコール酸8%からなる抱合型胆汁酸混合液を10mM以上含有する培地で生育可能なものであり、かつ浸透圧耐性能が、浸透圧2.2 Osmol/kg以上の培地で生育可能なものである菌株。 Lactobacillus gasseri strain having bile acid resistance and osmotic pressure resistance ,
Conjugated bile acid mixture consisting of 24% glycocholic acid, 24% glycochenodeoxycholic acid, 18% glycodeoxycholic acid, 13% taurocholic acid, 13% taurochenodeoxycholic acid and 8% taurodeoxycholic acid A strain that can grow on a medium containing 10 mM or more of the osmotic pressure, and that can grow on a medium having an osmotic pressure resistance of osmotic pressure of 2.2 Osmol / kg or more.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001144841A JP4671384B2 (en) | 2001-05-15 | 2001-05-15 | New lactic acid strain |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001144841A JP4671384B2 (en) | 2001-05-15 | 2001-05-15 | New lactic acid strain |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002335953A JP2002335953A (en) | 2002-11-26 |
JP4671384B2 true JP4671384B2 (en) | 2011-04-13 |
Family
ID=18990736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001144841A Expired - Fee Related JP4671384B2 (en) | 2001-05-15 | 2001-05-15 | New lactic acid strain |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4671384B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3648233B2 (en) | 2003-04-08 | 2005-05-18 | 明治飼糧株式会社 | Feed composition |
RU2006108554A (en) * | 2003-08-18 | 2007-09-27 | Дзе Байо Бэлэнс Корпорейшн (Us) | SUSTAINABLE LIQUID PROBIOTIC COMPOSITION, ITS PRODUCTION AND APPLICATIONS |
BRPI0923016A8 (en) * | 2008-12-19 | 2017-11-07 | Chr Hansen As | COMPOSITION OF BILE-RESISTANT BACILLI THAT SECRET HIGH LEVELS OF ESSENTIAL AMINO ACIDS |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06501624A (en) * | 1991-07-25 | 1994-02-24 | プロビ エービー | Intestinal colonizing Lactobacillus |
JPH07250670A (en) * | 1994-03-11 | 1995-10-03 | Calpis Food Ind Co Ltd:The | Lactic acid bacteria of genus lactobacillus |
JPH0974995A (en) * | 1995-09-12 | 1997-03-25 | Prima Meat Packers Ltd | Lactobacillus originated from intestinal tract and unheated edible meat product produced by using the lactobacillus |
JP2000189105A (en) * | 1998-12-25 | 2000-07-11 | Takanashi Milk Products Co Ltd | Functional food or drink having serum lipid improving effect |
JP2000197469A (en) * | 1999-01-08 | 2000-07-18 | New Food Creation Gijutsu Kenkyu Kumiai | Functional food/drink having serum lipid-improving effect |
JP2001097870A (en) * | 1999-09-30 | 2001-04-10 | Snow Brand Milk Prod Co Ltd | Method for absorption of bile acid using lactic acid bacterium |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU748744B2 (en) * | 1997-02-11 | 2002-06-13 | Enterprise Ireland Trading As Bioresearch Ireland | Probiotic strains from lactobacillus salivarius and antimicrobial agents obtained therefrom |
ID29150A (en) * | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | USE OF LACTOBACILLUS SALIVARIUS |
-
2001
- 2001-05-15 JP JP2001144841A patent/JP4671384B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06501624A (en) * | 1991-07-25 | 1994-02-24 | プロビ エービー | Intestinal colonizing Lactobacillus |
JPH07250670A (en) * | 1994-03-11 | 1995-10-03 | Calpis Food Ind Co Ltd:The | Lactic acid bacteria of genus lactobacillus |
JPH0974995A (en) * | 1995-09-12 | 1997-03-25 | Prima Meat Packers Ltd | Lactobacillus originated from intestinal tract and unheated edible meat product produced by using the lactobacillus |
JP2000189105A (en) * | 1998-12-25 | 2000-07-11 | Takanashi Milk Products Co Ltd | Functional food or drink having serum lipid improving effect |
JP2000197469A (en) * | 1999-01-08 | 2000-07-18 | New Food Creation Gijutsu Kenkyu Kumiai | Functional food/drink having serum lipid-improving effect |
JP2001097870A (en) * | 1999-09-30 | 2001-04-10 | Snow Brand Milk Prod Co Ltd | Method for absorption of bile acid using lactic acid bacterium |
Also Published As
Publication number | Publication date |
---|---|
JP2002335953A (en) | 2002-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108783462B (en) | Industrial production method of intestinal probiotic preparation | |
CN110669697B (en) | Lactobacillus casei for high yield of short-chain fatty acid, culture method and application thereof | |
CN116676225B (en) | Lactobacillus rhamnosus LR-28 strain with nerve soothing and sleep aiding effects, fermentation product, hypnotic fungus group mixture and application | |
CN113444664B (en) | Lactobacillus brevis for producing gamma-aminobutyric acid and application thereof | |
CN111996147A (en) | Lactobacillus paracasei with triglyceride reducing function and application thereof | |
CN109022313B (en) | Lactobacillus plantarum | |
CN105132321A (en) | Enterococcus faecium, culture medium thereof for high-density solid-state fermentation, and high-density solid-state fermentation method | |
CN105995684A (en) | Preparation method of symbiotic microflora enzyme | |
CN111849853A (en) | Method for improving tolerance of lactic acid bacteria bile salt | |
Hwang et al. | Biomass production of Lactobacillus plantarum LP02 isolated from infant feces with potential cholesterollowering ability | |
JP4671384B2 (en) | New lactic acid strain | |
CN110607253B (en) | Streptococcus thermophilus and proliferation culture method and application thereof | |
JP2007028920A (en) | Fermented milk and method for producing the same | |
CN117264839A (en) | Application of saliva combined with lactobacillus MB1 in preparation of food and medicine for whitening and relieving gout | |
KR100609779B1 (en) | Lactic acid bacteria degrading alcohol and acetaldehyde | |
CN113881592B (en) | Lactobacillus reuteri and application thereof | |
CN113293101B (en) | Inactivation method and application of lactic acid bacteria | |
JP2004057020A (en) | Method for producing lactic acid bacterium | |
JPH05292947A (en) | Lactobacillus-acidophilus pn-ri-2-4, lactic acid bacterial formulation using the same and its production | |
TWI740073B (en) | Lactic acid bacteria crystal composition capable of promoting intestinal stem cell proliferation, antiviral, anti-inflammatory and anti-allergic effects and preparation method thereof. | |
CN113005051A (en) | Lactobacillus paracasei and application thereof | |
KR100299306B1 (en) | Lactic acid bacteria with high acid resistance and growth rate and excellent blood cholesterol lowering ability | |
CN102108337A (en) | Lactobacillus casei and application thereof | |
CN111154694A (en) | Microbial fermentation inoculant and preparation method and application thereof | |
CN112940989B (en) | Complex microbial inoculant with intelligence-developing function and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080425 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100319 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101007 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101203 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110112 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110117 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4671384 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140128 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140128 Year of fee payment: 3 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140128 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140128 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |